A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This study involves single and multiple doses of LY3202626 and will evaluate the effects of
LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single
increasing doses of LY3202626 will be given in capsule form. Part A will also include
itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B
will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days
with the study drug. Part C will last approximately 11-14 weeks. Part D will last
approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may
only enroll in one part.